Abstract
The burden of atherosclerosis is particularly high in western countries in terms of mortality and disability. The cerebral arteries (stroke or transient ischemic attack [TIA]), coronary arteries (myocardial infarction [MI]) and peripheral arteries (intermittent claudication [IC], ischemic limb) can be affected. Atherosclerosis may involve different mechanisms such as inflammation, platelet activation, endothelial damage, balance between proliferation and apoptosis of smooth muscle cells and oxidative stress. Research is focused to counteract each of these aspects. Many antithrombotic drugs are currently available and most of them act as inhibitors of platelet function. Aspirin, ticlopidine, clopidogrel and the combination of aspirin plus dipyridamole are widely used for primary (in high-risk patients) and secondary prevention of atherosclerotic diseases. Research of new pharmacological strategies is driven by the need to reduce the risk of bleeding associated with the use of antiplatelet drugs. In this context cilostazol, a type III phosphodiesterase inhibitor, has demonstrated antiplatelet and vasodilator effects with low rate of bleeding complications. This review will focus on the pharmacological properties of cilostazol and its use in the management of atherothrombotic vascular diseases.
Keywords: Atherosclerosis, antiplatelet agents, phosphodiesterase inhibitor, cilostazol, vascular prevention
Current Vascular Pharmacology
Title: Cilostazol in the Management of Atherosclerosis
Volume: 8 Issue: 3
Author(s): Fabrizio Sallustio, Federica Rotondo, Silvia Di Legge and Paolo Stanzione
Affiliation:
Keywords: Atherosclerosis, antiplatelet agents, phosphodiesterase inhibitor, cilostazol, vascular prevention
Abstract: The burden of atherosclerosis is particularly high in western countries in terms of mortality and disability. The cerebral arteries (stroke or transient ischemic attack [TIA]), coronary arteries (myocardial infarction [MI]) and peripheral arteries (intermittent claudication [IC], ischemic limb) can be affected. Atherosclerosis may involve different mechanisms such as inflammation, platelet activation, endothelial damage, balance between proliferation and apoptosis of smooth muscle cells and oxidative stress. Research is focused to counteract each of these aspects. Many antithrombotic drugs are currently available and most of them act as inhibitors of platelet function. Aspirin, ticlopidine, clopidogrel and the combination of aspirin plus dipyridamole are widely used for primary (in high-risk patients) and secondary prevention of atherosclerotic diseases. Research of new pharmacological strategies is driven by the need to reduce the risk of bleeding associated with the use of antiplatelet drugs. In this context cilostazol, a type III phosphodiesterase inhibitor, has demonstrated antiplatelet and vasodilator effects with low rate of bleeding complications. This review will focus on the pharmacological properties of cilostazol and its use in the management of atherothrombotic vascular diseases.
Export Options
About this article
Cite this article as:
Sallustio Fabrizio, Rotondo Federica, Di Legge Silvia and Stanzione Paolo, Cilostazol in the Management of Atherosclerosis, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112331
DOI https://dx.doi.org/10.2174/157016110791112331 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Recent Advances in Polymer-based Wound Dressings for the Treatment of Diabetic Foot Ulcer: An Overview of State-of-the-art
Current Drug Targets The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Intravitreal Dexamethasone Implant <i>versus</i> Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial
Current Drug Delivery Cellular and Physiological Effects of Short-Chain Fatty Acids
Mini-Reviews in Medicinal Chemistry Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Laser Treatment for Diabetic Macular Edema in the 21<sup>st</sup> Century
Current Diabetes Reviews Effects of Insulin on the Vasculature
Current Vascular Pharmacology Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery Depression, Antidepressants and Hypertensive Disorders of Pregnancy: A Systematic Review
Current Drug Safety Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials